Articles tagged with Prostate Cancer
Researchers found significant associations between PSA velocity and demographic characteristics like age, race, and diet. Men who gained or lost weight had distinct changes in PSA velocity, while African Americans had higher velocities on average.
Researchers have developed a new cell line to study prostate cancer and its effects on the body. Anti-nerve growth factor therapy shows promise in reducing skeletal pain associated with prostate cancer, outperforming morphine.
A study found that Ack1 is a key driver of tumor growth in prostate cancer, and its inhibition can slow tumor formation. The researchers also discovered an experimental drug called geldanamycin that can inhibit Ack1 activity by interfering with its molecular interactions.
A study of 24 patients found that MRI with an endorectal coil at 1.5T outperforms conventional body coils in staging prostate cancer. The results suggest a need for advances in coil technology to improve imaging at higher field strengths.
The study found that patients with rapid increases in PSA levels (PSAV) or quick doubling of PSA levels (PSADT) were more likely to experience cancer spread, recurrence, and death. These findings provide valuable pretreatment prognostic factors for prostate cancer.
A recent Columbia University study published in Nutrition and Cancer showed that Zyflamend reduces prostate cancer cell proliferation by up to 78% and induces cancer cell death. The research confirms Zyflamend's COX-1 and COX-2 anti-inflammatory effects, with independent anti-cancer benefits against prostate cancer cells.
A new study found that a vitamin D pill combination extended the lives of men with advanced prostate cancer by about eight months compared to those receiving chemotherapy and placebo. The pill, DN-101, also protected against major side effects of chemotherapy.
A Dutch study found that higher doses of radiotherapy significantly improved patient outcome over a five-year period. An anti-androgen therapy trial suggested early treatment can benefit locally advanced disease, while immunotherapy trials are showing promising results for androgen-independent prostate cancer.
A protein called TAP has been found to suppress prostate cancer growth and enhance the effects of vitamin E. High levels of TAP in normal prostate cells suggest it facilitates the transport of vitamin E into tissue and helps retain high concentrations.
Researchers developed nanoparticles that can target and deliver drugs to prostate cancer cells using aptamers, achieving highly specific and efficient tumour targeting. The bioconjugates successfully adhered to PSMA-positive prostate cancer cells and were rapidly internalised into the targeted cells.
Researchers discovered that calcitriol and QW-1624-F2-2 slowed prostate cancer progression in intact mice after 14 weeks of treatment, reducing tumor burden. However, chronic treatment showed side effects, highlighting the need for further studies to understand how these agents prevent prostate cancer.
A novel computational model predicts androgen receptor binding sites in the prostate cancer genome. Experimental verification confirms the accuracy of the model, providing new insights into prostate cancer biology.
Researchers found a unique molecular signature of fused genes in most prostate cancer tissue samples but not in benign tissue. The discovery could lead to a diagnostic test that detects the fused genes or their protein products, making it more accurate than current screening tests.
Researchers analyzed human genome variation in various populations to understand disease susceptibility, reproductive success and genetic disorders. Gene conversion played a critical role in shaping the genetic diversity of the Luteinizing Hormone/Chorionic Gonadotropin Beta cluster, which is associated with pregnancy success.
A study by Case Western Reserve University researchers found that apigenin, a plant flavonoid, slowed tumor growth in mice with prostate cancer. Apigenin also reduced IGF-1 levels associated with increased cancer risk and triggered cell self-destruction.
A study of 1,492 men found that annual PSA testing reduced the risk of dying from prostate cancer by 3.6%, while increasing the chances of diagnosis with curable cancers. The test measures levels of prostate-specific antigen, a protein produced by the prostate.
Researchers at UCLA have identified how an antibody blocks prostate cancer growth by signaling cells to stop growing and die. The discovery could lead to a new treatment targeting prostate stem cell antigen, also found in bladder and pancreatic cancers.
Researchers have identified a strong biomarker, MDM2, that predicts more aggressive forms of prostate cancer. This overexpression is associated with an increased chance of metastasis and death from the disease.
A study conducted between 1988 and 1995 found that radiation therapy significantly improved five- and 10-year prostate cancer-free survival rates. The treatment reduced the risk of recurrence, cancer spread, and overall mortality in patients with advanced stage prostate cancer.
A study by Fox Chase Cancer Center found no significant impact of type II diabetes on the initial profile or treatment outcomes of prostate cancer. However, men with type II diabetes experienced significantly worse long-term overall survival rates compared to those without diabetes.
A Fox Chase study found that men with a history of TURP (transurethral resection of the prostate) and an intermediate PSA level are at higher risk for prostate cancer recurrence. This misleads doctors about disease extent, potentially leading to less aggressive treatment.
A new study found that short-term hormone therapy can significantly improve the outlook for men with early-stage prostate cancer. Researchers discovered that testosterone suppression before and during radiotherapy reduced the risk of relapse by up to 44%.
A recent study has found that patients who are obese at age 40 and experience rapid weight gain have a higher risk of prostate cancer recurrence. The research, published by the American Association for Cancer Research, suggests that men who gained an average of three and a half pounds per year are more likely to experience biochemical ...
A study of 526 prostate cancer patients suggests that a man's body mass at different ages and adult weight gain can predict the risk of progression after surgery. Researchers found that obese men and those who gained weight quickly experienced biochemical failure more often.
Researchers found that pomegranate extract killed more cells at higher doses, and mice treated with pomegranate extract showed slowing of cancer progression and reduced PSA levels. The study adds to growing evidence that pomegranates have powerful agents against cancer.
Researchers at U-M have developed a new blood test for prostate cancer that uses 22 biomarkers to accurately identify cancerous samples. The test shows promise as a supplement or replacement for current PSA testing methods, which can produce false positives and unnecessary biopsies.
Mutations in the EphB2 gene are found in 15% of African-American men with a strong family history, compared to 5% without a history. This gene mutation is associated with an increased risk of prostate cancer in African-American men, particularly those with a family history.
Researchers found that a tumor suppressor gene Nkx3.1 plays a crucial role in protecting cells from oxygen damage, which can lead to prostate cancer. Antioxidants may be useful for prostate cancer prevention by regulating oxidative stress pathways.
A randomized trial found that high-dose radiation therapy reduced the risk of prostate cancer recurrence by 49% compared to conventional-dose therapy. The study showed improved biochemical control and local tumor control without significant differences in overall survival rates or adverse effects.
Men with high PSA levels prior to prostate removal surgery were significantly more likely to have advanced clinical stages of cancer and higher grade cancers in surgically removed tissue. Increasing PSA levels after surgery were also associated with increased risk of cancer recurrence.
A study found that nearly 60% of prostate cancer specimens received higher Gleason scores than original assignments, suggesting that pathologists are more likely to assign high scores to contemporary tumor samples. This 'Will Rogers phenomenon' may lead to a false sense of therapeutic accomplishment and skew mortality rates.
A Stanford study found that combining vitamin D and nonsteroidal anti-inflammatory drugs (NSAIDs) suppresses prostate cancer growth more effectively than using either drug alone. The researchers discovered a 25-70% reduction in cell growth when calcitriol was used with NSAIDs, with potential implications for new treatment options.
Prostate cancer cells manipulate Wnt signaling proteins to establish themselves in bone tissue, producing dense bony lesions characteristic of prostate cancer. The study found that altered levels of Wnt activity promote osteoblastic lesions, while high levels of DKK-1 inhibit Wnt activity, leading to highly osteolytic tumor lesions.
Activated vitamin D, when combined with NSAIDs, may offer a more tolerable treatment option for prostate cancer. The drug combination limits prostate cancer cell growth by targeting the same molecules attacked by NSAIDs, promoting the breakdown of prostaglandin hormones.
The National Foundation for Cancer Research (NFCR) and the Prostate Cancer Foundation have partnered with the Burnham Institute to develop a 3D culture system that simulates tumor microenvironments. This technology enables rapid testing of candidate drugs and has potential applications beyond cancer research.
Researchers found that activated Stat5 levels in prostate cancer cells predict disease progression and survival rates. Patients with high levels of activated Stat5 had a 15-year progression-free survival rate of 46% compared to 62% without activated Stat5.
Researchers found that immediate postoperative radiotherapy significantly improved biochemical progression-free survival for patients at risk of relapse, with a 74% success rate compared to 53%. Long-term follow-up is needed to assess its effects on distant metastases and survival.
A randomized, controlled trial found that comprehensive lifestyle changes, including a vegan diet and moderate exercise, can decrease PSA levels and inhibit prostate tumor growth in men with prostate cancer. The study suggests that making lifestyle changes may help prevent or reverse prostate cancer progression.
A new technique called the Checkerboard Tissue Microarray (TMA) Method has been developed to accurately predict prostate cancer aggressiveness. This method can help identify markers of aggressive tumors, potentially preventing thousands of men from undergoing unnecessary radical surgery and its severe side effects.
Researchers found that prostate tumor growth is arrested through cellular senescence, which stops cells from proliferating and responding to normal growth signals. Drugs that support p53 function may delay progression of prostate cancer by triggering cellular senescence.
Lowering PSA cutoff from 4.0 ng/mL to 2.5 ng/mL would call for more biopsies, with 10.7% of US men aged 50-59 and 17% of those aged 60-69 affected.
Researchers identified three key risk factors for lethal prostate cancer recurrence after surgery: PSA doubling time, time from surgery to recurrence, and Gleason score. These risk factors allow doctors to distinguish between patients who need further treatment and those who can be closely monitored.
A study found that a rapid increase in PSA levels (PSA velocity) is associated with a higher risk of death from prostate cancer following radiation therapy. Men with low-risk disease and high PSA velocity had a 19% 7-year mortality rate, compared to 0% for those with low PSA velocity.
A study found that PSA doubling time, pathological Gleason score, and time from surgery to biochemical recurrence are significant risk factors for prostate-specific death. Patients at high risk can be identified and offered aggressive treatment, while those at low risk can be safely observed.
A population-based case control study found that PSA screening of asymptomatic men significantly reduces the risk of metastatic prostate cancer. The researchers discovered a 35% protective effect, even among men not screened regularly.
Men with prostate cancer are 10% less likely to be working six months after diagnosis compared to those without the disease. However, approximately two-thirds of patients continue to work due to fear of losing health insurance coverage, often at reduced hours and with decreased productivity.
A new study found long-duration regular use of aspirin or NSAIDs may lower prostate cancer risk by 18%. Gene variants associated with melanoma risk were also identified in a Mediterranean population study, while another study found no link between gene mutations and response to bevacizumab
The largest study to date provides valuable insights into flexible sigmoidoscopy screening among 154,942 participants aged 55-74. Findings show that women are more likely to decline FSG than men, while non-acceptance increases with age in women. The rate of cancer detected was 2.9 per 1,000 individuals screened.
The study analyzed data from a randomized, prospective trial to determine the effectiveness of PSA testing. Researchers found that no single cutoff value would simultaneously yield high sensitivity and specificity, highlighting the need for re-education on the concept of 'normal' PSA levels.
A recent Mayo Clinic study found a significant association between benign prostate obstruction and chronic kidney disease in older men. BPH can cause bladder outlet obstruction, leading to increased risk of death, hospitalization, and cardiovascular events.
Researchers found that the GSTP1 gene is temporarily inactivated through hypermethylation, increasing the risk of prostate cancer in African-Americans compared to Caucasians. The study suggests that GSTP1 hypermethylation may serve as a potential biomarker for prostate cancer diagnosis and treatment.
Researchers found men with high sun exposure had half the risk of prostate cancer compared to those with low sun exposure. Men with certain gene variants showed a 65% reduced risk, suggesting sunlight helps reduce prostate cancer risk through vitamin D production.
A new study has shown that PET with 11C-Choline improves the early diagnosis of relapsed prostate cancer, with a sensitivity of 65% compared to 28% for conventional FDG. This finding is particularly useful for detecting relapses in patients with low PSA levels.
A study of 1500 men with locally confined prostate cancer found that delaying radiation therapy did not affect overall survival, disease-specific survival, or treatment failure rates. This research provides reassurance for patients considering delayed treatment, allowing them to make informed decisions.
Researchers have identified ERG as the first proto-oncogene commonly overexpressed in early-phase prostate cancer, providing a promising target for diagnosis and treatment. The study also found correlations between ERG expression and PSA recurrence-free survival of prostate cancer patients after radical prostatectomy.
Prostate cancer patients who have a spouse or partner report lower levels of depression and emotional distress. Support groups can also benefit single men in improving their quality of life.
A study found that men with prostate cancer who are in a relationship report better mental health, greater spirituality, and fewer urinary symptoms. The researchers conclude that clinicians should address coping mechanisms to encourage the benefits of partnership and mitigate the negative effects of being single.
Researchers found that dutasteride suppresses blood flow in benign prostate tissue, enabling targeted biopsies to detect cancer more effectively. This reduction in benign blood flow improved cancer detection rates and may reduce the need for repeat biopsies.
Researchers have identified MMP-7 as a key player in prostate cancer-driven bone destruction, revealing a potential therapeutic target for controlling cancer-induced bone loss. The study's findings suggest that MMP inhibitors may be effective in interrupting osteolysis and promoting bone growth.
Researchers at Oregon Health & Science University developed a nomogram to identify men with high-grade prostate cancer and those who can be closely monitored. The chart uses clinical variables such as age, digital rectal exam findings, and PSA density to predict tumor grade, reducing the need for biopsies.